Ltz Therapeutics

Ltz Therapeutics company information, Employees & Contact Information

Explore related pages

Related company profiles:

LTZ Therapeutics is an immunotherapy-focused global biotech company pursuing innovative therapies in oncology and autoimmune diseases. Pioneering a novel myeloid engager platform that is guided by reverse translational science, emerging disease biology, and leveraging the power of myeloid cell subsets, particularly macrophages, which offer tremendous potential as an effective therapy to improve the lives of patients with the bold aim to one day eliminate cancer.

Company Details

Employees
36
Founded
-
Address
Redwood City, California 94065, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Manager jobs.
HQ
Redwood City, California
Looking for a particular Ltz Therapeutics employee's phone or email?

Ltz Therapeutics Questions

News

LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases - Business Wire

LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases Business Wire

LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301 - Business Wire

LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301 Business Wire

LTZ bags $40 million as it sends first myeloid engager into clinic - The Pharma Letter

LTZ bags $40 million as it sends first myeloid engager into clinic The Pharma Letter

FDA Clears IND Application for LTZ-301 in non-Hodgkin Lymphoma - Targeted Oncology

FDA Clears IND Application for LTZ-301 in non-Hodgkin Lymphoma Targeted Oncology

LTZ Therapeutics’ myeloid engager gains IND clearance - BioWorld MedTech

LTZ Therapeutics’ myeloid engager gains IND clearance BioWorld MedTech

Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics - BioWorld MedTech

Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics BioWorld MedTech

LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases - Business Wire

LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases Business Wire

Top Ltz Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant